John M Leonard sold $836k of NTLA
President and CEO at Intellia Therapeutics, Inc.. 88,146 shares at an average of $9.49, traded Dec 11, 2025, filed Dec 12, 2025.
Score components
- +25RoleCEO
- +23Trade size$836k at market
- 0Share of holdings soldSold 7.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-317551, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | MOption exercise Common Stock10b5-1 | +49,959 | $6.83 | $341k | 1,127,074 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stock10b5-1 | -49,959 | $9.49 | $474k | 1,077,115 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stock10b5-1 | -32,832 | $9.47 | $311k | 1,044,283 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stock10b5-1 | -5,355 | $9.59 | $51k | 1,038,928 | Dec 12, 2025 |
| Dec 12, 2025 | MOption exercise Common Stock10b5-1 | +8,557 | $6.83 | $58k | 1,047,485 | Dec 12, 2025 |
| Dec 11, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -49,959 | $0.00 | $0 | 8,557 | Dec 12, 2025 |
| Dec 12, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -8,557 | $0.00 | $0 | 0 | Dec 12, 2025 |
Related signals
Other insiders at Intellia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NTLAsell Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $23k 1,864 shares | -3% | |
| 23Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $17k 1,211 shares | -1% | |
| 23Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $8,364 607 shares | -1% | |
| 40Moderate | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $96k 10,397 shares | -9% | |
| 39Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $88k 9,515 shares | -10% | |
| 58Moderate | NTLAbuy Intellia Therapeutics, Inc. | Fred E Cohen director | $1.4M 150,000 shares | +261% | |
| 35Weak | Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $28k 2,989 shares | -5% | |
| 44Moderate | Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $59k 6,379 shares | -6% | |
| 40Moderate | Intellia Therapeutics, Inc. | David Lebwohl EVP, Chief Medical Officer | $110k 11,903 shares | -9% | |
| 39Weak | Intellia Therapeutics, Inc. | Birgit C Schultes EVP, Chief Scientific Officer | $78k 8,508 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.